Diabetic
kidney disease (DKD) is a major complication of diabetes and the leading cause
of end-stage renal failure. Epigenetics has been associated with metabolic
memory, in which prior periods of hyperglycemia enhance the future risk of
developing DKD despite subsequent glycemic control. To understand the mechanistic
role of such epigenetic memory in human DKD and identify new therapeutic
targets, we profiled gene expression, DNA methylation, and chromatin
accessibility in kidney proximal tubule epithelial cells (PTECs) derived from non-diabetic
and Type-2 diabetic (T2D) subjects. T2D-PTECs displayed persistent gene
expression and epigenetic changes with and without TGFβ1 treatment, even after
culturing in vitro under similar
conditions as non-diabetic PTECs, signified by deregulation of fibrotic and transport
associated genes (TAGs). Motif-analysis of differential DNA methylation and
chromatin accessibility regions associated with genes differentially regulated
in T2D revealed enrichment for SMAD3, HNF4A, and CTCF transcription factor
binding sites. Furthermore, the downregulation of several TAGs in T2D (including
CLDN10, CLDN14, CLDN16, SLC16A2, SLC16A5) was associated
with promoter hypermethylation, decreased chromatin accessibility and reduced
enrichment of HNF4A, histone H3-lysine-27-acetylation, and CTCF. Together,
these integrative analyses reveal epigenetic memory underlying the deregulation
of key target genes in T2D-PTECs that may contribute to sustained renal dysfunction
in DKD.
Funding
This work was supported by grants from the National Institutes of Health (NIH), R01 DK081705, R01 DK058191 and R01 HL106089 (to R.N.), and R00HL122368, R01HL145170, and Ella Fitzgerald Foundation (to Z.C.). The research reported here included work performed in the Integrative Genomics Core supported by the National Cancer Institute of the NIH under grant number P30CA033572.